This trial will help determine the best way to treat anemia in patients with aSAH, and whether doing so impacts mortality and functional outcomes.
1 Primary · 10 Secondary · Reporting Duration: 12 months post
Active Control
Experimental Treatment
740 Total Participants · 2 Treatment Groups
Primary Treatment: Liberal RBC Transfusion Strategy · No Placebo Group · N/A
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: